Results 71 to 80 of about 292 (134)
Familiar Dermatologic Drugs as Therapies for COVID-19. [PDF]
Actas Dermosifiliogr, 2021 Ortega-Peña M, González-Cuevas R.
europepmc +1 more source
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab. [PDF]
Reumatol Clin (Engl Ed), 2020 Figuero-Pérez L +5 more
europepmc +1 more source
[Poor prognostic factors in patients hospitalized for COVID-19]. [PDF]
An Sist Sanit Navar, 2022 Blanco-Taboada AL +5 more
europepmc +1 more source
Evaluación clínica y calidad de vida de pacientes con sintomatología persistente tras la infección por sars-cov-2 [PDF]
Antecedentes El SARS-COV-2 es un virus de ARN monocatenario que conduce a una tormenta de citocinas e inflamación sistémica con afectación multiorgánica.
Marín Real, Sonia
core
COVID-19 and cardiovascular disease. [PDF]
Clin Investig Arterioscler, 2020 Guijarro C.
europepmc +1 more source
La tormenta de citocinas en COVID-19. Entrevistando a Iván Chérrez
Revista Alergia México, 2020 Diana Andrea Herrera-Sánchez
doaj
[Biological therapy as an alternative treatment for cytokine release syndrome in patients with COVID-19]. [PDF]
Rev Colomb Reumatol, 2022 Solis Cartas U.
europepmc +1 more source
[Therapeutic Options for the Management of Severe COVID-19: A Rheumatology Perspective]. [PDF]
Reumatol Clin, 2021 Mendoza-Pinto C +3 more
europepmc +1 more source